clinical trial · NCT05903274
JSP191 (briquilimab) in Subjects with LR-MDS
Lower-risk Myelodysplastic SyndromeJSP191
brief summary
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
started
Jun 19, 2023
primary completion
Oct 21, 2024
completion
Oct 21, 2024
last updated
Feb 27, 2025
detailed description
An open-label, single-arm, dose-escalation study designed to determine the potential safety, efficacy, maximum tolerated dose (MTD) or optimal biologic dose (OBD), and recommended phase 2 dose (RP2D) of JSP191 (briquilimab) monotherapy for LR-MDS subjects with documented cytopenia (red blood cell-transfusion dependent, thrombocytopenia, and/or neutropenia).
official title
A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol